All In Biotech

Drug Trial Radar · NCT06343805

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

A Phase 1, Open-Label Study of LY5830966, a Type II JAK2 Inhibitor, in Patients With Myelofibrosis Previously Treated With a Type I JAK2 Inhibitor, JAK2 Inhibitor-Naïve Myelofibrosis, or High-risk Relapsed/Refractory Polycythemia Vera

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

256

Planned (sponsor's estimate)

Start

Oct 3, 2024

Primary completion

Jun 2027

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

J8G-MC-JDIA (AJX-101) is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II Janus Kinase 2 (JAK2) inhibitor, LY5830966, in participants with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.

Conditions

  • Primary Myelofibrosis

Interventions

  • LY5830966Drug

    Type II JAK2 Inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with treatment-emergent adverse events (TEAEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0).Time frame: Baseline through study completion, an average of 1 year
  2. Number of patients with Dose Limiting Toxicities (DLTs)Time frame: Baseline through study completion, an average of 1 year
  3. To establish the maximum tolerated dose (MTD) and/or recommended phase 3 dose (RP3D) of LY5830966Time frame: Baseline through study completion, an average of 1 year

Locations

21 sites in 5 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Institute

    Palo Alto, California · Recruiting

  • Moffitt Cancer Cancer Center

    Tampa, Florida · Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • AP-HP Hopital Saint-Louis

    Paris, France · Recruiting

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola

    Bologna, Italy, Italy · Not yet recruiting

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy, Italy · Not yet recruiting

  • Hospital Clinic Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain · Recruiting

  • Hospital General Universitario Gregorio Maranon

    Madrid, Spain, Spain · Recruiting

  • Guy's Hospital

    London, UK, United Kingdom · Not yet recruiting

  • Genesis Cancer Care UK Limited - Oxford

    Oxford, UK, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.